SEBI-registered analyst Dhruv Tuli of Ascend Wealth noted Cipla’s strong technical breakout backed by momentum and volume, ...

Major players such as Sun Pharma, Dr. Reddy’s Laboratories, Cipla, Divi’s Laboratories, Aurobindo Pharma, Lupin, and Biocon ...

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

Cipla's stock experienced a significant drop of 2.34% in early trading, making it one of the top losers on the Nifty 50 index.

As Cipla turns 90, the pharmaceutical giant is reimagining itself as a brand fit for a wellness-driven, digital-first India.

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

Cipla posted a 10.3% rise in Q1 profit with stable EBITDA margins and strong gross margin expansion helping offset pressure ...

ICICI Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1800 in its research ...

Cipla shares experienced a significant 2.6% increase on Monday, positioning the company among the top gainers on the Nifty 50 index.

Cipla has acquired a 20% stake in iCaltech Innovations for Rs 5 crore to expand its respiratory care and diagnostics ...

Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...